Alclometasone Dipropionate
(Synonyms: 阿氯米松双丙酸酯,Sch 22219) 目录号 : GC40638
A corticosteroid
Cas No.:66734-13-2
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Alclometasone dipropionate (ACM) is a corticosteroid. It reduces cutaneous anaphylaxis reactions induced by tuberculin or albumin in mice when administered topically (20 μl of a 0.1% solution). ACM also inhibits androgen-dependent cytochrome P450 activity and the O-depropylation activity of 7-alkoxy-coumarin O-dealkylase in a dose-dependent manner in male rats but has no effect on hepatic drug metabolism in female rats or mice of both sexes. Formulations containing ACM have been used to treat radiation and allergic contact dermatitis.
| Cas No. | 66734-13-2 | SDF | |
| 别名 | 阿氯米松双丙酸酯,Sch 22219 | ||
| Canonical SMILES | O=C1C=C[C@@]2(C)C(C[C@@H](Cl)[C@]3([H])[C@]2([H])[C@@H](O)C[C@@]4(C)[C@@]3([H])C[C@@H](C)[C@@]4(C(COC(CC)=O)=O)OC(CC)=O)=C1 | ||
| 分子式 | C28H37ClO7 | 分子量 | 521 |
| 溶解度 | DMF: 30 mg/ml,DMSO: 30 mg/ml,Ethanol: 30 mg/ml,Ethanol:PBS(pH 7.2) (1:1): 0.2 mg/ml | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.9194 mL | 9.5969 mL | 19.1939 mL |
| 5 mM | 0.3839 mL | 1.9194 mL | 3.8388 mL |
| 10 mM | 0.1919 mL | 0.9597 mL | 1.9194 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Alclometasone Dipropionate in psoriasis: a clinical study
J Int Med Res 1982;10(6):414-8.PMID:7152079DOI:10.1177/030006058201000605.
In a parallel group design, and using a 'blind evaluator' technique, alclometasone cream 0.05% and clobetasone butyrate cream 0.5% applied twice a day for 21 days were compared in thirty-one patients presenting with psoriasis. Erythema, induration and scaling were assessed at the start of treatment. Seven, 14 and 21 days later, effects of the two treatments were assessed and recorded together with the physician's global evaluation of overall improvement. Both drugs had similar beneficial effects on the clinical signs. No adverse experience was reported and the overall results indicate that alclometasone and clobetasone have comparable efficacy and safety.
Alclometasone Dipropionate cream 0.05% versus clobetasone butyrate cream 0.05%. A controlled clinical comparison in the treatment of atopic dermatitis in children
Int J Dermatol 1984 Oct;23(8):565-6.PMID:6389385DOI:10.1111/j.1365-4362.1984.tb04214.x.
A randomized, double-blind, parallel-group study was conducted comparing the efficacy and safety of Alclometasone Dipropionate cream 0.05% and clobetasone butyrate cream 0.05% in the treatment of atopic dermatitis in 43 children. The medications were applied to study areas as a thin layer of cream twice daily for 2 weeks. Efficacy was assessed by evaluation of three disease signs (erythema, induration, and pruritus) and by mean of a physician's global evaluation following treatment. Safety was evaluated through patient-reported and clinically observed adverse experiences. Both treatments were effective. At the end of the trial, average reduction in disease signs was 85% for alclometasone dipropionate-treated patients and 86% in the clobetasone butyrate-treated group. In the global evaluation, the physician rated symptoms as cleared in 9 of 22 alclometasone dipropionate-treated patients and in 10 of 21 clobetasone butyrate-treated patients.
Clinical comparison of Alclometasone Dipropionate cream 0.05% with hydrocortisone butyrate cream 0.1% in the treatment of atopic dermatitis in children
J Int Med Res 1983;11(5):315-9.PMID:6357892DOI:10.1177/030006058301100512.
Alclometasone Dipropionate cream 0.05% was compared to hydrocortisone butyrate cream 0.1% in the treatment of atopic dermatitis in forty children, 5 to 11 years old. In this double-blind, parallel-group trial, the experimental creams were applied twice daily for 2 weeks, without occlusion, to the study areas. Efficacy was evaluated 1 and 2 weeks after the start of treatment. Both creams were effective treatments for atopic dermatitis; however, Alclometasone Dipropionate was judged slightly more efficacious. Improvement in erythema, induration, and pruritus averaged 76% for alclometasone dipropionate-treated patients and 70% for hydrocortisone butyrate-treated patients. At the end of treatment, the physician's global evaluation indicated nineteen of twenty patients in the Alclometasone Dipropionate group had between 51% and 100% improvement in disease signs and symptoms, compared with sixteen of twenty patients treated with hydrocortisone butyrate. Two patients in the alclometasone dipropionate-treated group and one in the hydrocortisone butyrate-treated group reported mild stinging.
The effect of Alclometasone Dipropionate cream 0.05% on the hypothalamic-pituitary-adrenal axis of normal volunteers
J Int Med Res 1985;13(5):276-80.PMID:4054428DOI:10.1177/030006058501300505.
In an open study of ten evaluable normal volunteers, 30 g of Alclometasone Dipropionate cream 0.05% was applied to 80% of body surface each morning and evening for 21 days. A plastic body suit effectively occluded the treated area for 12 hours/day. As demonstrated by continued normal levels of 8 a.m. plasma cortisol and 24-hour urinary 17-hydroxysteroid and free cortisol, no suppression of the hypothalamic-pituitary-adrenal axis occurred. Local adverse reactions were mild and transient.
Clinical comparison of Alclometasone Dipropionate and desonide ointments (0.05%) in the management of psoriasis
J Int Med Res 1982;10(5):375-8.PMID:6754511DOI:10.1177/030006058201000511.
This was a double-blind, randomized, parallel-groups comparison of Alclometasone Dipropionate and desonide ointments (0.05%) applied twice daily without occlusion for 3 weeks by patients with moderate to severe psoriasis. Data from thirty-three patients in each group showed that both treatments produced rapid amelioration of erythema, induration, and, especially, scaling; substantial improvement was evident after 1 week and continued thereafter. Differences between the groups were not statistically significant, but trends consistently favoured alclometasone. No adverse drug reaction occurred.